ClinicalTrials.gg
TerminatedNCT03425097Updated Feb 17, 2021Results posted

Fexofenadine Use in Gastroesophageal Reflux Symptoms

A Phase 2 interventional study of Fexofenadine and Placebo - Cap in Gastroesophageal Reflux, sponsored by Stanford University. Terminated at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2021-02-17.

Sponsored by Stanford University · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to insufficient evidence for Fexofenadine efficacy to treat GERD symptoms after the interim analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 421 studies in Gastroesophageal Reflux with a site in United States — 55 open to participants now, 70 under way, 2 of them phase 3. Gastroesophageal Reflux · United States.

Enrollment
259th of 302
11 · median 60
Started
2018
with 10 others
Phase 2
35 of 421
2 open now
Registered
316th of 421
by date

Among the 421 studies in Gastroesophageal Reflux with a site in United States, this one is the 259th largest by enrollment of the 302 interventional ones that give a count, is one of 11 that started in 2018, is one of 35 in phase 2, and was the 316th registered.

Gastroesophageal Reflux

1,215 studies on the registry are indexed under Gastroesophageal Reflux; 203 are open to participants now.

Browse Gastroesophageal Reflux studies →

Open to participants now

55 of the 421 studies in Gastroesophageal Reflux with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 133 Gastroesophageal Reflux studies recruiting now, 57 (43%) set no upper age limit and 53 (40%) stop at 75 or younger; 22 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 421 studies in Gastroesophageal Reflux with a site in United States, or all of them as a file.
02

Study summary

The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite being on a proton pump inhibitor. The investigators will do this by giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know which drug they are getting at a particular time. This will help the investigators better assess the true effectiveness of Fexofenadine.

Read the detailed description

Around 18-28% of North American adults have gastroesophageal reflux symptoms once per week. Of those patients up to 60% may have an inadequate response to proton pump inhibitors and have persistent symptoms. One possible explanation is that this group of patients has nerve related pain. It is thought that H1 receptor activation may sensitize the gastrointestinal tract and esophagus to pain. H1 blockers such as anti-histamines may play a role in treatment of gastroesophageal reflux symptoms that are refractory to proton pump inhibitors by reducing pain perception. The investigators wish to conduct a randomized control trial to test this hypothesis. The investigators will do this by giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill) for 2 weeks. The participants will not know which drug they are getting at a particular time. This will help the investigators better assess the true effectiveness of Fexofenadine.

03

Conditions studied

  • Gastroesophageal Reflux
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A minimum 6-month history of heartburn and regurgitation, as their main symptom
  • Experience at least 3-4 days with episodes of heartburn or regurgitation per week
  • Female patients who are or using acceptable methods of .

Exclusion criteria

Exclusion Criteria (selected)

  • Esophageal stricture
  • Primary esophageal motility disorder
  • Systemic sclerosis
  • Active inflammatory bowel disease
  • Zollinger-Ellison syndrome
  • Active gastric or duodenal ulcer
  • Active infectious or inflammatory conditions of the small or large intestine
  • Malabsorption syndromes of the intestine
  • History of gastrointestinal cancer
  • Current active cancer
  • Prior gastric or intestinal surgery
  • Pregnant or breast feeding
  • Other serious psychiatric or medical disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Fexofenadine then Placebo

    Patients in this group will get 2 weeks of fexofenadine, then 1 week of nothing, then 2 weeks of placebo.

    Drug: Fexofenadine · Drug: Placebo - Cap

  • Experimental
    Placebo then Fexofenadine

    Patients in this group will get 2 weeks of placebo, then 1 week of nothing, then 2 weeks of fexofenadine.

    Drug: Fexofenadine · Drug: Placebo - Cap

Interventions

  • Fexofenadine 180 mg in the morning

  • DrugPlacebo - Cap

    Placebo cap in the morning

06

What researchers measure

Primary outcomes

  1. Mean Percent of Days With Reflux

    Time frame: 2 weeks per treatment

  2. Mean Number of Reflux Episodes Per Day

    Time frame: 2 weeks per treatment

  3. Mean GERD-HRQL Questionnaire Score

    The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total.

    Time frame: 2 weeks per treatment

  4. Mean Symptom Severity Score

    Severity of reflux symptoms on a scale of 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe)

    Time frame: 2 weeks per treatment

  5. Mean Rescue Medications Per Day

    Medications such as Tums or Pepcid can be used if reflux symptoms are severe and relief is needed (additional doses of proton pump inhibitors are not allowed beyond the regular dosing)

    Time frame: 2 weeks per treatment

Secondary outcomes

  1. Patient Medication Preference

    Patients will be asked which medication they think better helps treat their reflux symptoms, placebo or Fexofenadine.

    Time frame: Will be assessed at the end of the trial (total trial time is 6 weeks)

  2. Count of Participants With Side Effects

    Patients will write down side effects at the end of each treatment period. If severe patients should seek medical attention immediately and report the side effects to us.

    Time frame: Will be assessed at the end of the initial treatment period (2 weeks) and at the end of the crossover period (2 weeks)

07

Results

Posted Feb 17, 2021
Limitations and caveats
This study was underpowered as it did not meet its planned sample size of 40 participants.

Participant flow

Treatment Period 1 (2 Weeks)
Participant flow — Treatment Period 1 (2 Weeks)
MilestoneFexofenadine Then PlaceboPlacebo Then Fexofenadine
Started65
Completed65
Not completed00
Washout Period (1 Week)
Participant flow — Washout Period (1 Week)
MilestoneFexofenadine Then PlaceboPlacebo Then Fexofenadine
Started65
Completed65
Not completed00
Second Treatment Period (2 Weeks)
Participant flow — Second Treatment Period (2 Weeks)
MilestoneFexofenadine Then PlaceboPlacebo Then Fexofenadine
Started65
Completed65
Not completed00

Outcome measures

PrimaryMean Percent of Days With Reflux
Time frame:
2 weeks per treatment
Reported as:
Mean · percentage of days
Mean Percent of Days With Reflux
percentage of daysRun-in PeriodFexofenadinePlacebo
Mean Percent of Days With Reflux83.4 (59.4 to 107.4)52.4 (4.3 to 100.4)52.4 (12.5 to 92.2)
PrimaryMean Number of Reflux Episodes Per Day
Time frame:
2 weeks per treatment
Reported as:
Mean · episodes
Mean Number of Reflux Episodes Per Day
episodesRun-in PeriodFexofenadinePlacebo
Mean Number of Reflux Episodes Per Day1.74 (0.73 to 2.75)0.69 (-0.01 to 1.40)0.67 (-0.05 to 1.29)
PrimaryMean GERD-HRQL Questionnaire Score

The questionnaire consists of 10 questions with responses of 0-5. The responses of the 10 questions are totaled (range of 0-50) where a higher total indicates more severe disease than a lower total.

Time frame:
2 weeks per treatment
Reported as:
Mean · score on a scale
Mean GERD-HRQL Questionnaire Score
score on a scaleRun-in PeriodFexofenadinePlacebo
Mean GERD-HRQL Questionnaire Score16.2 (2.5 to 29.8)9.8 (-1.5 to 21.2)12.3 (4.0 to 20.7)
PrimaryMean Symptom Severity Score

Severity of reflux symptoms on a scale of 0-4 (0=none, 1=mild, 2=moderate, 3=severe, 4=very severe)

Time frame:
2 weeks per treatment
Reported as:
Mean · score on a scale
Mean Symptom Severity Score
score on a scaleRun-in PeriodFexofenadinePlacebo
Mean Symptom Severity Score1.2 (0.6 to 1.9)0.8 (-0.03 to 1.5)0.7 (-0.02 to 1.4)
PrimaryMean Rescue Medications Per Day

Medications such as Tums or Pepcid can be used if reflux symptoms are severe and relief is needed (additional doses of proton pump inhibitors are not allowed beyond the regular dosing)

Time frame:
2 weeks per treatment
Reported as:
Mean · medications
Mean Rescue Medications Per Day
medicationsRun-in PeriodFexofenadinePlacebo
Mean Rescue Medications Per Day0.29 (-0.31 to 0.89)0.52 (-0.75 to 1.80)0.17 (-0.14 to 0.47)
SecondaryPatient Medication Preference

Patients will be asked which medication they think better helps treat their reflux symptoms, placebo or Fexofenadine.

Time frame:
Will be assessed at the end of the trial (total trial time is 6 weeks)

No measurements were reported for this outcome.

SecondaryCount of Participants With Side Effects

Patients will write down side effects at the end of each treatment period. If severe patients should seek medical attention immediately and report the side effects to us.

Time frame:
Will be assessed at the end of the initial treatment period (2 weeks) and at the end of the crossover period (2 weeks)
Reported as:
Count of participants · Participants
Count of Participants With Side Effects
ParticipantsFexofenadinePlacebo
Count of Participants With Side Effects10

Adverse events

Collected over 6 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Fexofenadine0/11 (0%)0/11 (0%)1/11 (9.1%)
Placebo0/11 (0%)0/11 (0%)0/11 (0%)
Most frequent other events
Most frequent other events
EventFexofenadinePlacebo
NosebleedRespiratory, thoracic and mediastinal disorders1/110/11

Baseline characteristics

Age, Customized
Age, Customized(Participants)All Participants
40-49 years1
50-59 years1
60-69 years2
70-79 years1
80-89 years1
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female2
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino0
Not Hispanic or Latino9
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
United States11
08

Study locations

1 site
  • Stanford Health Care
    Redwood City, California 94063, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2018 to primary completion in Jan 2019, 11 months.

Results were first posted in Feb 2021, 2 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2018
First posted
Feb 7, 2018
StartActual
Feb 7, 2018
Primary completionActual
Jan 8, 2019
CompletionActual
Jan 8, 2019
Results first posted
Feb 17, 2021
Last update
Feb 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03425097
Responsible party
Thomas Zikos (Fellow in Gastroenterology, Stanford University) — Principal investigator
First posted
Feb 7, 2018
Start date
Feb 7, 2018
Primary completion
Jan 8, 2019
Completion
Jan 8, 2019
Results posted
Feb 17, 2021
Last update
Feb 17, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fexofenadine

Start the discussion